What do patients with low-risk thyroid cancer actually want to know? Not what surgeons think they want to know, or what informed consent requirements dictate, but what patients themselves prioritize when given the chance to ask questions during a surgical consultation. A study published in Surgery, with Dr. Susan Pitt as senior author, set out to answer this question by doing something deceptively simple: they recorded real conversations between patients and surgeons, and they listened.
253 Questions, 28 Patients
The research team audio-recorded consultations between 30 patients with clinically low-risk thyroid cancer and 9 surgeons across two academic medical centers. They identified 253 substantive questions — not logistical queries about scheduling or parking, but genuine clinical questions that revealed what patients were thinking about as they faced a treatment decision. The median patient asked 8 questions, though the range was enormous: from zero to 25.
The questions clustered around five major themes: the extent of surgery (lobectomy versus total thyroidectomy), thyroid hormone supplementation after surgery, the risk of cancer progression or recurrence, radioactive iodine treatment, and the underlying cause of their cancer. Notably, many of the most frequent questions were not about the surgery itself but about life after surgery — what would change, what would be permanent, and what the new normal would look like.
The Gap Between Question and Answer
The most revealing finding was not what patients asked but how surgeons responded. When patients probed for a direct recommendation about the extent of surgery — "What would you do?" or "What do you recommend?" — surgeons often responded indirectly, presenting options without making a clear recommendation. While this approach aligns with principles of shared decision-making, it sometimes left patients feeling unsupported in a moment when they were looking for guidance.
Even more striking was the disconnect in quality-of-life conversations. When patients asked about how surgery might affect their daily lives — their energy, their voice, their ability to function normally — surgeons tended to redirect toward oncologic benefits and surgical risks. The patient was asking about living; the surgeon was answering about survival. Both conversations are important, but they are not the same conversation, and the gap between them represents a missed opportunity for genuine shared decision-making.
Hormone Replacement and the Unspoken Concern
One of the most commonly asked questions — about thyroid hormone supplementation — reveals a concern that is often underappreciated by surgeons. For patients, the prospect of taking daily medication for the rest of their lives is not a minor inconvenience. It represents a fundamental change in their relationship with their own body: a permanent reminder that something was removed, that they are now dependent on a pill to function normally. Surgeons accustomed to managing thyroid hormone replacement as routine may underestimate the psychological weight this carries for patients encountering it for the first time.
Similarly, questions about radioactive iodine — a treatment that many patients with low-risk cancer will never need — revealed anxiety about treatments that had been mentioned in passing or discovered through internet searches. Patients were often worrying about possibilities that were clinically remote, but the worry was real and deserved direct, compassionate engagement rather than dismissal.
Patients are not asking the questions we expect them to ask. They are asking about the life they will lead after treatment — and we owe it to them to answer those questions as carefully as we answer the ones about cancer.